MCID: OCL006
MIFTS: 53

Ocular Hypertension

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Ocular Hypertension

MalaCards integrated aliases for Ocular Hypertension:

Name: Ocular Hypertension 12 54 44 15 17 70
Hypertension, Ocular 39

Classifications:



External Ids:

Disease Ontology 12 DOID:9282
ICD9CM 34 365.04
MeSH 44 D009798
NCIt 50 C3285
SNOMED-CT 67 267721003
ICD10 32 H40.05
UMLS 70 C0028840

Summaries for Ocular Hypertension

Disease Ontology : 12 An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss.

MalaCards based summary : Ocular Hypertension, also known as hypertension, ocular, is related to glaucoma, primary open angle and intraocular pressure quantitative trait locus, and has symptoms including eye manifestations An important gene associated with Ocular Hypertension is MYOC (Myocilin), and among its related pathways/superpathways are p70S6K Signaling and NFAT and Cardiac Hypertrophy. The drugs Triamcinolone and Dorzolamide have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 73 Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure),... more...

Related Diseases for Ocular Hypertension

Diseases related to Ocular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 glaucoma, primary open angle 31.8 TMCO1 TGFB2 RHO PTGFR OPTN MYOC
2 intraocular pressure quantitative trait locus 31.7 TMCO1 TGFB2 PTGFR OPTN MYOC CA2
3 open-angle glaucoma 31.3 TMCO1 TGFB2 RHOA RHO PTGFR OPTN
4 steroid-induced glaucoma 30.7 TGFB2 NR3C1 MYOC
5 glaucoma, normal tension 30.7 TMCO1 OPTN MYOC
6 macular degeneration, age-related, 1 30.4 TGFB2 RLBP1 RHO MYOC AKT1
7 traumatic glaucoma 30.3 TMCO1 MYOC
8 glaucoma-related pigment dispersion syndrome 30.3 TMCO1 OPTN MYOC
9 eye disease 30.1 TGFB2 RLBP1 RHO OPTN MYOC AKT1
10 retinal disease 30.1 RLBP1 RHO OPTN MYOC
11 chronic closed-angle glaucoma 30.0 TGFB2 MYOC
12 exudative vitreoretinopathy 1 29.8 RHO MYOC MTOR EPO
13 glaucoma 1, open angle, a 29.7 OPTN MYOC
14 acute closed-angle glaucoma 29.6 OPTN MYOC
15 body mass index quantitative trait locus 11 29.4 SERPINA6 RHOA NR3C1 MTOR JUN HSD11B1
16 retinitis pigmentosa 29.2 RLBP1 RHOA RHO MYOC MTOR JUN
17 glaucoma 3, primary congenital, a 10.9
18 glaucoma 3, primary infantile, b 10.9
19 hydrophthalmos 10.9
20 yemenite deaf-blind hypopigmentation syndrome 10.6
21 optic nerve disease 10.6
22 uveitis 10.6
23 cataract 10.5
24 macular retinal edema 10.4
25 myopia 10.4
26 exfoliation syndrome 10.4
27 retinal vein occlusion 10.4
28 conjunctivitis 10.3
29 retinal detachment 10.3
30 ocular hyperemia 10.3
31 iridocyclitis 10.3
32 combined hepatocellular carcinoma and cholangiocarcinoma 10.3 MTOR AKT1
33 peripheral retinal degeneration 10.3 RLBP1 RHO MYOC
34 solar retinopathy 10.3 RLBP1 RHO
35 microvascular complications of diabetes 5 10.3
36 refractive error 10.3
37 acute stress disorder 10.3 NR3C1 FKBP5 FKBP4
38 vitreous disease 10.3 TGFB2 RLBP1 RHO
39 keratitis, hereditary 10.2
40 malt worker's lung 10.2 MYOC FOS
41 corticosteroid-binding globulin deficiency 10.2 SERPINA6 NR3C1 FKBP5
42 diabetic macular edema 10.2
43 optic nerve hypoplasia, bilateral 10.2 TMCO1 RLBP1 RHO MYOC
44 vitreoretinopathy, neovascular inflammatory 10.2 TGFB2 RLBP1 FOS
45 retinal ischemia 10.2
46 neovascular glaucoma 10.2
47 neuropathy 10.2
48 lens disease 10.2 TGFB2 RHO MYOC
49 in situ carcinoma 10.2 NR3C1 FKBP4 AKT1
50 allergic conjunctivitis 10.2

Comorbidity relations with Ocular Hypertension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle

Graphical network of the top 20 diseases related to Ocular Hypertension:



Diseases related to Ocular Hypertension

Symptoms & Phenotypes for Ocular Hypertension

UMLS symptoms related to Ocular Hypertension:


eye manifestations

MGI Mouse Phenotypes related to Ocular Hypertension:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 AKT1 CA2 EPO FKBP4 FKBP5 FOS
2 growth/size/body region MP:0005378 10.32 AKT1 CA2 FKBP4 FKBP5 FOS HSD11B1
3 immune system MP:0005387 10.31 AKT1 CA2 EPO FOS HSD11B1 JUN
4 cellular MP:0005384 10.3 AKT1 EPO FKBP4 FOS HSD11B1 JUN
5 cardiovascular system MP:0005385 10.28 AKT1 EPO FKBP4 FOS HSD11B1 JUN
6 embryo MP:0005380 10.25 AKT1 EPO FKBP4 FKBP5 FOS JUN
7 mortality/aging MP:0010768 10.25 AKT1 CA2 EPO FKBP4 FKBP5 FOS
8 endocrine/exocrine gland MP:0005379 10.24 AKT1 CA2 FKBP4 FOS HSD11B1 JUN
9 nervous system MP:0003631 10.18 AKT1 CA2 FKBP5 FOS HSD11B1 JUN
10 normal MP:0002873 9.96 AKT1 EPO FKBP5 FOS JUN MTOR
11 no phenotypic analysis MP:0003012 9.87 JUN MTOR MYOC NR3C1 OPTN RHO
12 renal/urinary system MP:0005367 9.81 CA2 FKBP4 FKBP5 MTOR NR3C1 RHOA
13 respiratory system MP:0005388 9.56 AKT1 CA2 EPO HSD11B1 JUN MTOR
14 skeleton MP:0005390 9.32 AKT1 CA2 EPO FOS JUN MTOR

Drugs & Therapeutics for Ocular Hypertension

Drugs for Ocular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
3
Dipivefrin Approved Phase 4 52365-63-6 3105
4
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
5
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
6
Sorbitol Approved Phase 4 50-70-4 5780
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
8
Carteolol Approved Phase 4 51781-06-7 2583
9
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
10
Rimexolone Approved Phase 4 49697-38-3 39507
11
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
14
Brinzolamide Approved Phase 4 138890-62-7 68844
15 Triamcinolone diacetate Phase 4
16 Triamcinolone hexacetonide Phase 4
17 triamcinolone acetonide Phase 4
18 Anti-Infective Agents, Local Phase 4
19 Lubricant Eye Drops Phase 4
20 Benzalkonium Compounds Phase 4
21 Carbonic Anhydrase Inhibitors Phase 4
22 Adrenergic alpha-Agonists Phase 4
23 Adrenergic Agonists Phase 4
24 Brimonidine Tartrate Phase 4 70359-46-5
25 Anti-Allergic Agents Phase 4
26 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4
27 Respiratory System Agents Phase 4
28 Anti-Asthmatic Agents Phase 4
29 Bronchodilator Agents Phase 4
30 Dermatologic Agents Phase 4
31 Mitomycins Phase 4
32 Sympatholytics Phase 4
33 Norgestimate, ethinyl estradiol drug combination Phase 4
34 Gastrointestinal Agents Phase 4
35 Antiemetics Phase 4
36 Antibiotics, Antitubercular Phase 4
37 Pharmaceutical Solutions Phase 4
38
Adenosine Approved, Investigational Phase 3 58-61-7 60961
39
Apraclonidine Approved Phase 3 66711-21-5 2216
40
tannic acid Approved Phase 3 1401-55-4
41
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
42
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
43
Betaxolol Approved, Investigational Phase 3 659-18-7, 63659-18-7 2369
44
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 9552079 2713
45
Pilocarpine Approved, Investigational Phase 3 92-13-7, 54-71-7 5910
46
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
47
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
48
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
49
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
50
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0

Interventional clinical trials:

(show top 50) (show all 567)
# Name Status NCT ID Phase Drugs
1 IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy Unknown status NCT02471105 Phase 4 Preserved Bimatoprost 0.01%;Tafluprost Unit Dose Preservative Free 15microgram/ml
2 A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma Unknown status NCT02231515 Phase 4
3 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% Unknown status NCT01444040 Phase 4 Travoprost
4 Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom Unknown status NCT01125306 Phase 4
5 An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension. Unknown status NCT00442312 Phase 4 Combigan Ophthalmic Solutiom
6 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
7 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
8 A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan). Completed NCT00847483 Phase 4 latanoprost 0.005% ophthalmic solution;Travoprost 004% sterile ophthalmic solution;Bimatoprost .03% sterile ophthalmic solution
9 Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs Completed NCT00675207 Phase 4 Brimonidine purite 0.15%;Dorzolamide 2%;Brinzolamide 1%
10 A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study) Completed NCT00887029 Phase 4 DuoTrav (travoprost-timolol ophthalmic drops);Xalacom (latanoprost-timolol ophthalmic drops)
11 Study of the Efficacy of Brinzolamide 1% Plus Brimonidine 0.2% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Rise After Nd-YAG Laser Capsulotomy Completed NCT03192826 Phase 4 Brinzolamide/Brimonidine FC;Brimonidine 0.2%;Artificial tears
12 Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Patients With Open-Angled Glaucoma or Ocular Hypertension Completed NCT01471158 Phase 4 Brinzolamide/Timolol Maleate Fixed Combination (AZARGA);Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
13 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan® Completed NCT00708422 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
14 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN® Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
15 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
16 Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
17 Ocular Surface Conditions in Asian Glaucoma Patients With Existing Corneal Disorders Switching From Preserved Prostaglandin Analogues Monotherapy to Preservative-free Tafluprost Completed NCT04654611 Phase 4 preservative free tafluprost 0.0015%
18 Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Completed NCT03104621 Phase 4 Benzalkonium chloride (BAK);0.0015% tafluprost
19 The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs. Completed NCT01655758 Phase 4 0.5% timolol;timolol-dorzolamide fixed combination;Latanoprost;Travoprost;Bimatoprost
20 A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
21 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension Completed NCT00541242 Phase 4 bimatoprost 0.03% eye drops;latanoprost 0.005% eye drops
22 Randomized, Investigator Masked Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4 Istalol and Optive;Alphagan
23 An Open-label, Phase IV, Pilot Study, to Evaluate Confocal Microscopic Findings of Cornea, Ocular Signs and Symptoms in Patients With OH or OAG Switching From Latanoprost 0.005% to Preservative Free Tafluprost 0.0015% Eye Drops Completed NCT01369771 Phase 4 Tafluprost 0.0015%
24 The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma. Completed NCT02338362 Phase 4 Fluticasone propionate inhaler;Saline placebo inhaler
25 A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
26 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
27 Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue Completed NCT01937312 Phase 4 Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension;Vehicle;Prostaglandin analogue
28 Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost Completed NCT01937299 Phase 4 Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension;Vehicle;Travoprost 0.004% ophthalmic solution
29 Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
30 Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Completed NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
31 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Completed NCT00735449 Phase 4 Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%;timolol maleate 0.5%;latanoprost 0.005%
32 Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg Completed NCT00647101 Phase 4 Latanoprost
33 An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z® Completed NCT00799682 Phase 4 Xalatan;Travatan Z
34 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
35 Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
36 Health-Related Quality of Life in Two Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: an Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty Versus Medical Therapy Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
37 A 2-year, Multicenter, Double-masked, Randomized, Parallel Study of the Safety of LUMIGAN® 0.1 mg/mL Compared With LUMIGAN® 0.3 mg/mL in Patients With Glaucoma or Ocular Hypertension Completed NCT01298700 Phase 4 bimatoprost 0.01% ophthalmic solution;bimatoprost 0.03% ophthalmic solution
38 Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
39 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% Completed NCT01443988 Phase 4 Travoprost
40 Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension Completed NCT00761995 Phase 4 Azopt;Cosopt
41 Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. Completed NCT00941096 Phase 4 Bimatoprost and Bimatoprost/Timolol fixed combination.
42 Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma Completed NCT01664039 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
43 Safety and Efficacy of Using the Travoprost/Timolol Fixed Combination (DuoTrav®) in Patients With Open-Angle Glaucoma or Uncontrolled Ocular Hypertension by Beta-blocker Monotherapy (Timolol 0.5%) Completed NCT01336569 Phase 4 Travoprost 0.004%/timolol maleate 0.5% fixed combination
44 Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan® Completed NCT01170884 Phase 4 fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution;bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
45 A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
46 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
47 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822081 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
48 A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting Completed NCT03808688 Phase 4 Netarsudil Ophthalmic Solution 0.02%
49 Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01253902 Phase 4 bimatoprost ophthalmic solution 0.01%;travoprost ophthalmic solution 0.004%;latanoprost ophthalmic solution 0.005%
50 A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension Completed NCT01525173 Phase 4 0.1% brimonidine tartrate ophthalmic solution;0.01% bimatoprost ophthalmic solution;0.2% hypromellose lubricant eye drops;latanoprost 0.005% ophthalmic solution

Search NIH Clinical Center for Ocular Hypertension

Inferred drug relations via UMLS 70 / NDF-RT 51 :


apraclonidine
Apraclonidine hydrochloride
Mannitol
Mannitol hexanitrate
MANNITOL PWDR
Urea
UREA POWDER

Cochrane evidence based reviews: ocular hypertension

Genetic Tests for Ocular Hypertension

Anatomical Context for Ocular Hypertension

MalaCards organs/tissues related to Ocular Hypertension:

40
Eye, Retina, Endothelial, Bone Marrow, Kidney, Lung, Thyroid

Publications for Ocular Hypertension

Articles related to Ocular Hypertension:

(show top 50) (show all 5284)
# Title Authors PMID Year
1
Assessment of SNPs associated with the human glucocorticoid receptor in primary open-angle glaucoma and steroid responders. 54 61
20376328 2010
2
[Expression of glucocorticoid receptors alpha and beta in mononuclear cells of peripheral blood in patients with glucocorticoid-induced ocular hypertension]. 54 61
19484926 2009
3
Overexpression of myocilin in the Drosophila eye activates the unfolded protein response: implications for glaucoma. 61 54
19148291 2009
4
Aqueous humor myocilin protein levels in normal, genetic carriers, and glaucoma Beagles. 54 61
18435660 2008
5
Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. 61 54
17615537 2007
6
The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy. 61 54
17563720 2007
7
Myocilin-associated exosomes in human ocular samples. 61 54
17094967 2007
8
Coiled-coil targeting of myocilin to intracellular membranes. 61 54
16973161 2006
9
Novel myocilin mutation in a Chinese family with juvenile-onset open-angle glaucoma. 54 61
16401791 2006
10
Characterization of rabbit myocilin: Implications for human myocilin glycosylation and signal peptide usage. 54 61
12697062 2003
11
Myocilin glaucoma. 54 61
12504739 2002
12
Rapid mutation detection by the transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma. 54 61
11815346 2002
13
Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. 54 61
11431441 2001
14
Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. 61 54
11133859 2001
15
Characterization and differential expression of a human gene family of olfactomedin-related proteins. 61 54
11006633 2000
16
Detection of SARS-CoV-2 RNA in the corneal epithelium of a patient after recovery from COVID-19. 61
33748538 2021
17
The outcome of surgical treatment in advanced glaucoma. 61
32654827 2021
18
Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E2 receptor EP2 subtype. 61
33811074 2021
19
Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. 61
33629227 2021
20
Capturing heterogeneity in repeated measures data by fusion penalty. 61
33517583 2021
21
Long-term follow-up of intraocular pressure and pressure-lowering medication in patients following Excimer laser trabeculotomy. 61
33289863 2021
22
Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. 61
32606078 2021
23
COVID-19 Related Ocular Hypertension Secondary to Anterior Uveitis as Part of a Multi-systemic Inflammatory Syndrome. 61
33710069 2021
24
Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles. 61
33719796 2021
25
Outcomes of pattern scanning laser trabeculoplasty and selective laser trabeculoplasty: Results from the lausanne laser trabeculoplasty registry. 61
32602256 2021
26
siRNA targeting Schlemm's canal endothelial tight junctions enhances outflow facility and reduces IOP in a steroid-induced OHT rodent model. 61
33376757 2021
27
The Canonical Wnt Signaling Pathway Inhibits the Glucocorticoid Receptor Signaling Pathway in the Trabecular Meshwork. 61
33705750 2021
28
Predicting the safety zone for steroid-induced ocular hypertension induced by intravitreal dexamethasone implantation. 61
33737305 2021
29
Characterization of the role of autophagy in retinal ganglion cell survival over time using a rat model of chronic ocular hypertension. 61
33707562 2021
30
Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy. 61
33757333 2021
31
Airborne particulate matter (PM2.5) triggers ocular hypertension and glaucoma through pyroptosis. 61
33663554 2021
32
A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma. 61
33244711 2021
33
A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. 61
33733980 2021
34
A Porcine Organ-Culture Glaucoma Model Mimicking Trabecular Meshwork Damage Using Oxidative Stress. 61
33704361 2021
35
Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis. 61
33137015 2021
36
Gonioscopic iridocorneal angle morphology and incidence of postoperative ocular hypertension and glaucoma in dogs following cataract surgery. 61
32649053 2021
37
Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma. 61
33734910 2021
38
Is laser trabeculoplasty the new star in glaucoma treatment? 61
33470670 2021
39
UVEITIS TREATED WITH DEXAMETHASONE IMPLANT. 61
32618834 2021
40
Osteopontin activates retinal microglia causing retinal ganglion cells loss via p38 MAPK signaling pathway in glaucoma. 61
33559950 2021
41
Systematic review of clinical research on regenerative medicine for the cornea. 61
33591470 2021
42
Contributing ocular comorbidity to end-of-life visual acuity in medically treated glaucoma patients, ocular hypertension and glaucoma suspect patients. 61
32494040 2021
43
A "shining" example of interstitial keratitis. 61
33437893 2021
44
Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension. 61
33757401 2021
45
NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs. 61
33704360 2021
46
Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis. 61
33783352 2021
47
Characteristics and Treatment Patterns of Newly Diagnosed Open-Angle Glaucoma Patients in the United States: An Administrative Database Analysis. 61
32927109 2021
48
Six-Year Incidence and Risk Factors of Primary Glaucoma in the Singapore Indian Eye Study. 61
32947057 2021
49
Sampling trabecular meshwork using TrabEx. 61
33740938 2021
50
Association of Genetic Polymorphisms in Oxidative Stress and Inflammation Pathways with Glaucoma Risk and Phenotype. 61
33803434 2021

Variations for Ocular Hypertension

Expression for Ocular Hypertension

Search GEO for disease gene expression data for Ocular Hypertension.

Pathways for Ocular Hypertension

Pathways related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 TGFB2 RHOA MTOR JUN FOS AKT1
2
Show member pathways
12.89 TGFB2 RHOA MTOR JUN AKT1
3
Show member pathways
12.85 NR3C1 MTOR JUN FOS AKT1
4
Show member pathways
12.84 MTOR JUN FOS EPO AKT1
5
Show member pathways
12.8 TGFB2 MTOR JUN FOS AKT1
6
Show member pathways
12.77 TGFB2 RHOA MTOR JUN FOS AKT1
7 12.76 TGFB2 RHOA MTOR JUN FOS EPO
8
Show member pathways
12.74 RHOA MTOR JUN FOS AKT1
9
Show member pathways
12.68 TGFB2 MTOR JUN FOS AKT1
10
Show member pathways
12.61 RHOA MTOR JUN FOS AKT1
11
Show member pathways
12.48 MTOR JUN FOS AKT1
12 12.45 RHOA JUN FOS AKT1
13 12.44 RHOA MTOR JUN AKT1
14
Show member pathways
12.43 RHOA JUN FOS AKT1
15
Show member pathways
12.43 TGFB2 RHOA MTOR JUN FOS
16 12.37 TGFB2 JUN FOS AKT1
17 12.36 RHOA JUN FOS AKT1
18
Show member pathways
12.36 RHOA NR3C1 MTOR JUN FOS AKT1
19 12.33 TGFB2 RHOA MTOR AKT1
20
Show member pathways
12.33 RHOA JUN FOS AKT1
21
Show member pathways
12.32 MTOR JUN FOS AKT1
22
Show member pathways
12.31 RHOA MTOR JUN FOS AKT1
23
Show member pathways
12.29 TGFB2 JUN FOS AKT1
24
Show member pathways
12.23 RHOA JUN FOS AKT1
25 12.21 MTOR JUN FOS AKT1
26
Show member pathways
12.2 MTOR JUN FOS AKT1
27
Show member pathways
12.19 JUN FOS EPO AKT1
28 12.16 RHO MTOR JUN AKT1
29
Show member pathways
12.15 RHOA JUN FOS AKT1
30 12.12 MTOR JUN FOS AKT1
31
Show member pathways
12.12 RHOA PTGFR MTOR JUN FOS AKT1
32 12.1 RHOA JUN FOS AKT1
33
Show member pathways
12.09 MTOR JUN FOS AKT1
34 12.08 RHOA JUN FOS AKT1
35
Show member pathways
12.07 RHOA JUN FOS AKT1
36 12.06 RHOA JUN FOS AKT1
37
Show member pathways
12.01 RHOA MTOR JUN FOS
38 11.99 JUN FOS FKBP5 FKBP4 AKT1
39
Show member pathways
11.97 RHOA JUN FOS AKT1
40 11.93 TGFB2 JUN AKT1
41 11.91 MTOR JUN FOS AKT1
42 11.9 TGFB2 JUN FOS
43 11.89 RHOA FOS AKT1
44
Show member pathways
11.86 JUN FOS AKT1
45 11.84 RHOA JUN FKBP4 AKT1
46 11.8 RHOA JUN FOS
47 11.76 RHOA MTOR AKT1
48 11.75 TGFB2 JUN AKT1
49 11.75 NR3C1 JUN FOS AKT1
50
Show member pathways
11.74 NR3C1 JUN FOS

GO Terms for Ocular Hypertension

Cellular components related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor AP-1 complex GO:0035976 8.62 JUN FOS

Biological processes related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 TGFB2 PTGFR JUN EPO AKT1
2 aging GO:0007568 9.78 JUN FOS EPO AKT1
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 TGFB2 MYOC EPO
4 response to organic substance GO:0010033 9.74 JUN CA2 AKT1
5 positive regulation of cell growth GO:0030307 9.72 TGFB2 RHOA AKT1
6 SMAD protein signal transduction GO:0060395 9.7 TGFB2 JUN FOS
7 response to mechanical stimulus GO:0009612 9.69 RHOA JUN FOS
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.67 MTOR JUN AKT1
9 response to lipopolysaccharide GO:0032496 9.67 PTGFR JUN FOS EPO
10 positive regulation of neuron apoptotic process GO:0043525 9.63 TGFB2 RHOA JUN
11 positive regulation of stress fiber assembly GO:0051496 9.58 RHOA MYOC MTOR
12 regulation of glycogen biosynthetic process GO:0005979 9.56 MTOR AKT1
13 anoikis GO:0043276 9.54 MTOR AKT1
14 cellular response to reactive oxygen species GO:0034614 9.5 JUN FOS AKT1
15 transforming growth factor beta receptor signaling pathway GO:0007179 9.46 TGFB2 RHOA JUN FOS
16 heart valve morphogenesis GO:0003179 9.43 TGFB2 MTOR
17 cellular response to cadmium ion GO:0071276 9.43 JUN FOS AKT1
18 negative regulation of cell size GO:0045792 9.13 RHOA MTOR AKT1
19 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 8.92 TGFB2 NR3C1 JUN FOS

Molecular functions related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 FK506 binding GO:0005528 9.16 FKBP5 FKBP4
2 11-cis retinal binding GO:0005502 8.96 RLBP1 RHO
3 steroid binding GO:0005496 8.8 SERPINA6 NR3C1 HSD11B1

Sources for Ocular Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....